Hosted on MSN
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff?
Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The settlement comes after years ...
Cassava Sciences (SAVA) fell ~14% in the premarket on Friday after the company said it will be forced to delay a clinical trial for its lead candidate, simufilam, for a form of epilepsy, as it moves ...
Cassava Sciences (SAVA) announced on Thursday that the Fraud Section of the U.S. Department of Justice has closed an investigation into the company over allegations related to its research misconduct.
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ...
AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ...
Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday. Cassava Sciences said the FDA had placed a ...
Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.
Interested in writing for CW? Compliance Week accepts outside contributions from corporate chief compliance officers and other senior-level GRC practitioners. To learn more, contact the CW Editor.
The Department of Justice (DOJ) building in Washington, D.C., U.S., November 28, 2025. REUTERS/Nathan Howard Feb 19 (Reuters) - Cassava Sciences said on Thursday the U.S. Department of Justice had ...
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results